Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054433 | 0.87 | MAOB (0.82) | MAOBALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL12243083 | 0.86 | ALOX5 (0.53) | MAOBALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL7739310 | 0.86 | NPC1 (0.63) | MAOBALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3722771 | 0.83 | MAOB (0.60) | MAOBALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL9126144 | 0.83 | MAOB (0.90) | MAOBALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6338480 | 0.82 | MAOB (0.73) | MAOBALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL23483149 | 0.81 | ALOX5 (0.79) | MAPTNPC1P2RY14SMPD1FFAR1 | |
| SCHEMBL5921632 | 0.80 | MRGPRX4 (0.76) | MAOBALDH1A1SMN1; SMN2MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL8380168 | 0.79 | MRGPRX4 (0.74) | MAOBALDH1A1SMN1; SMN2MAPTNPC1 | |
| SCHEMBL5582767 | 0.78 | NR4A2 (0.81) | MAOBSMN1; SMN2NPC1FFAR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | MAOB 3765/4885ALDH1A1 4746/4885HTT 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.